Title:
FUSION PROTEIN DIMER COMPRISING PD-1 AND IL-15 AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/048518
Kind Code:
A1
Abstract:
The present invention relates to a fusion protein comprising the PD-1 protein and IL-15 protein, and a use thereof. The fusion protein including PD-1, IL-15, and prolonged serum persistent Fc according to a specific embodiment can activate immune cells such as NK cells and effectively increase the half-life of the immune cells in the body. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient increases immune activity in the body and thus can be utilized as an anticancer drug for patients who do not respond to immune checkpoint inhibitor treatment and relapsed patients.
Inventors:
SUH JUNG-KEUN (KR)
Application Number:
PCT/KR2022/014304
Publication Date:
March 30, 2023
Filing Date:
September 23, 2022
Export Citation:
Assignee:
BIONSYSTEMS INC (KR)
International Classes:
C07K14/705; A61K38/00; A61P35/00; C07K14/54; C12N15/62
Domestic Patent References:
| WO2021119429A1 | 2021-06-17 |
Foreign References:
| KR20190060821A | 2019-06-03 | |||
| KR20210058902A | 2021-05-24 | |||
| KR20190123723A | 2019-11-01 |
Other References:
XU YUANMING, CARRASCOSA LUCIA CAMPOS, YEUNG YIK ANDY, CHU MATTHEW LING-HON, YANG WENJING, DJURETIC IVANA, PAPPAS DANIELLE C., ZEYT: "An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity", CANCER IMMUNOLOGY RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 10, 1 October 2021 (2021-10-01), US , pages 1141 - 1157, XP093054460, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-21-0058
Attorney, Agent or Firm:
RYU, Jong Woo et al. (KR)
Download PDF:
Previous Patent: ELECOTRNIC DEVICE AND METHOD FOR E2 RETENTION IN COMMUNICATION SYSTEM
Next Patent: CHILLER
Next Patent: CHILLER